Microbot Medical Announces Commencement of Pivotal Study for its Self-Cleaning Shunt

- October 1st, 2018

Following the successful outcome of the initial study, Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced the commencement of a follow up pivotal study to evaluate the safety and efficacy of the Company’s Self-Cleaning Shunt (SCS™). As quoted in the press … Continued

Following the successful outcome of the initial study, Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced the commencement of a follow up pivotal study to evaluate the safety and efficacy of the Company’s Self-Cleaning Shunt (SCS™).

As quoted in the press release:

The Company’s innovative SCS is designed to be a transformative device which prevents obstruction in the cerebrospinal fluid (CSF) catheters implanted in the ventricle of the brain of patients who suffer from hydrocephalus or Normal Pressure Hydrocephalus (NPH).

The follow up study will be conducted by leading hydrocephalus experts at Washington University in St. Louis, MO and Wayne State University in Detroit, MI.  The study will include a larger sample size compared to the initial study and the primary and secondary endpoints will seek to validate the safety and efficacy of the SCS that will be activated in both in-vitro (lab) and in-vivo (animal) models.  The Company believes the follow up study will continue to support the safety and efficacy of its SCS product and plans to use the findings for its regulatory submissions in the US, Europe and other jurisdictions.

Click here to read the full press release.

Read our FREE medical device report today

 

 

Get My Free Report  

Tags

Leave a Reply